Good Prospects For Athenex/Almirall Following PhIII Actinic Keratosis Results
Executive Summary
Two Phase III studies of KX2-391 to treat actinic keratosis of the face and scalp met their primary endpoint of 100% clearance. The treatment could prove more convenient than marketed therapies.
You may also be interested in...
Finance Watch: Five IPOs Launch In Two Days; Three Remain In Positive Territory
Public Company Edition: Trevi Therapeutics was the first out of the gate on 7 May, but four more biopharma firms went public in the US on 8 May, while just 13 IPOs launched between January and April. Also, new financings include debt for BMS, Bausch and Intercept.
Almirall Taps Evotec For Novel Dermatology Mechanism
The Spanish derma specialist has agreed a research collaboration that could yield novel therapies for diseases such as psoriasis and atopic dermatitis.
Almirall Inks 'Transformational Deal' Buying Allergan's US Derma Portfolio
Buying Allergan's US dermatology portfolio will expand the Spanish group's platform in the world's largest dermatology market.